TCHP Regimen Dosing and Administration for HER2-Positive Invasive Ductal Carcinoma
The TCHP regimen (docetaxel, carboplatin, trastuzumab, pertuzumab) is administered as follows: docetaxel 75 mg/m² IV, carboplatin AUC 6 IV, trastuzumab 8 mg/kg IV loading dose then 6 mg/kg IV, and pertuzumab 840 mg IV loading dose then 420 mg IV, all given on day 1 of each 21-day cycle. 1, 2, 3
Standard Dosing Schedule
Initial Cycle (Day 1):
- Docetaxel: 75 mg/m² IV infusion
- Carboplatin: AUC 6 IV infusion
- Trastuzumab: 8 mg/kg IV over 90 minutes (loading dose)
- Pertuzumab: 840 mg IV (loading dose)
Subsequent Cycles (Every 21 Days):
- Docetaxel: 75 mg/m² IV infusion
- Carboplatin: AUC 6 IV infusion
- Trastuzumab: 6 mg/kg IV over 30-90 minutes
- Pertuzumab: 420 mg IV
Treatment Duration and Context
For adjuvant/neoadjuvant settings: Administer chemotherapy (docetaxel/carboplatin) for 6 cycles (18 weeks), then continue trastuzumab ± pertuzumab to complete 1 year of HER2-directed therapy 1, 2, 3, 4. The TCHP regimen is a preferred regimen for HER2-positive early breast cancer, particularly in node-positive disease 2, 3.
For metastatic disease: Continue treatment until disease progression or unacceptable toxicity 5, 6.
Critical Administration Details
- All agents are given intravenously—never as IV push or bolus 4
- Do not substitute trastuzumab products for ado-trastuzumab emtansine or other HER2-targeted agents 4
- Avoid concurrent anthracyclines with trastuzumab/pertuzumab due to significant cardiac toxicity risk 2, 1
Cardiac Monitoring Requirements
Mandatory cardiac function assessment (LVEF by echocardiogram or MUGA):
- Baseline before treatment initiation
- During treatment: at 3,6, and 9 months 1, 4
- Baseline LVEF must be ≥55% to initiate therapy 7
Alternative Weekly Schedule
A weekly variant exists but is less commonly used:
- Paclitaxel (not docetaxel): 80 mg/m² IV days 1,8,15
- Carboplatin: AUC 2 IV days 1,8,15
- Trastuzumab: 4 mg/kg loading, then 2 mg/kg weekly
- Cycled every 28 days 1, 6
Key Clinical Considerations
Pertuzumab addition is strongly recommended for node-positive disease based on APHINITY trial data showing improved disease-free survival with dual HER2 blockade 3, 8. The CLEOPATRA trial demonstrated that pertuzumab + trastuzumab + docetaxel achieved superior progression-free survival (18.5 vs 12.4 months) compared to trastuzumab + docetaxel alone in metastatic disease 6.
Common toxicities include neutropenia (expect grade 3-4 in ~25% with taxane-platinum regimens), diarrhea, and fatigue 7, 9. The TCHP regimen avoids anthracycline-related cardiotoxicity while maintaining efficacy 1, 2.
Pathological complete response rates with TCHP ± pertuzumab range from 44-66%, with higher rates observed when pertuzumab is included 7, 9, 10.